UBS initiated coverage on AI-driven drug discovery firm Insilico Medicine (03696.HK) with a "Buy" rating and a HKD77 price target, citing its platform's potential to radically shorten pharmaceutical development timelines.
The bullish outlook is based on Insilico's end-to-end proprietary Pharma.AI platform, which the bank noted is a global leader in the sector. "UBS said INSILICO integrates generative AI, deep learning and automation to shorten the timeline from target discovery to preclinical candidate (PCC) nomination from the traditional approximately 4.5 years to 12 to 18 months," the report stated.
This accelerated timeline has allowed the Pharma.AI platform to generate around 30 pipeline assets and underpin more than 10 licensing or collaboration agreements. As of May 2026, the total contract value of these deals exceeded $7 billion, with the drug discovery and pipeline development segment accounting for 87% of the company's total revenue in 2025.
For investors, UBS projects Insilico's revenue to see a compound annual growth rate of 36% over the 2025 to 2035 period. The HKD77 price target corresponds to a forecast 2026 price-to-sales ratio of 31.3x, a multiple UBS considers to be in line with global peers in the high-growth technology and biotech sectors.
A core component of the investment thesis is the company's leading asset, Rentosertib (ISM001-055). The report highlighted that Rentosertib is the world’s first first-in-class candidate to be fully discovered and designed using artificial intelligence.
The drug has already demonstrated favorable efficacy and safety in Phase 2a clinical results in China. Following this success, Insilico is planning to commence a pivotal Phase 3 trial for the candidate in China in the third quarter of 2026, a critical step toward potential commercialization.
The initiation from a major institution like UBS provides a strong vote of confidence in the AI-driven drug discovery (AIDD) model. While companies like Eli Lilly have found massive success with new-generation drugs developed through more traditional R&D, Insilico represents a different approach focused on technological efficiency.
The ability to move from target discovery to a preclinical candidate in under 18 months presents a significant cost and time advantage over the multi-year timelines common in the pharmaceutical industry. UBS appears optimistic about the future licensing potential from Insilico's expanding pipeline, suggesting a durable growth story if the platform continues to deliver promising drug candidates.
This article is for informational purposes only and does not constitute investment advice.
